David C. Rees

24.6k total citations · 6 hit papers
323 papers, 15.2k citations indexed

About

David C. Rees is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, David C. Rees has authored 323 papers receiving a total of 15.2k indexed citations (citations by other indexed papers that have themselves been cited), including 181 papers in Genetics, 143 papers in Hematology and 95 papers in Molecular Biology. Recurrent topics in David C. Rees's work include Hemoglobinopathies and Related Disorders (176 papers), Iron Metabolism and Disorders (110 papers) and Erythrocyte Function and Pathophysiology (47 papers). David C. Rees is often cited by papers focused on Hemoglobinopathies and Related Disorders (176 papers), Iron Metabolism and Disorders (110 papers) and Erythrocyte Function and Pathophysiology (47 papers). David C. Rees collaborates with scholars based in United Kingdom, United States and France. David C. Rees's co-authors include Thomas N. Williams, Mark T. Gladwin, Christopher W. Murray, J. B. Clegg, Michael J. Cox, Pedro H. H. Hermkens, H. C. J. OTTENHEIJM, Frédéric B. Piel, Martin H. Steinberg and Andrew L. Hopkins and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

David C. Rees

315 papers receiving 14.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sickle-cell disease

2010 1.7k citations David C. Rees et al. profile →
World distribution of factor V Leiden

1995 900 citations David C. Rees et al. profile →
The role of ligand efficiency metrics in drug discovery

2014 819 citations Andrew L. Hopkins, György M. Keserű et al. Nature Reviews Drug Discovery profile →
Sickle Cell Disease

2017 749 citations David C. Rees et al. profile →
The rise of fragment-based drug discovery

2009 580 citations David C. Rees et al. profile →
Structural homology of reaction centers from Rhodopseudomonas sphaeroides and Rhodopseudomonas viridis as determined by x-ray diffraction.

1986 229 citations David C. Rees et al. profile →

Peers

Countries citing papers authored by David C. Rees

Since Specialization

Citations

This map shows the geographic impact of David C. Rees's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David C. Rees with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David C. Rees more than expected).

Fields of papers citing papers by David C. Rees

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David C. Rees. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David C. Rees. The network helps show where David C. Rees may publish in the future.

Co-authorship network of co-authors of David C. Rees

This figure shows the co-authorship network connecting the top 25 collaborators of David C. Rees. A scholar is included among the top collaborators of David C. Rees based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David C. Rees. David C. Rees is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study 2024 ·Orphanet Journal of Rare Diseases ·Eliane Sardh, Manisha Balwani, David C. Rees, Karl E. Anderson, Gang Jia, Marianne T. Sweetser, Bruce Wang	1
2	Significant haemoglobinopathies: A guideline for screening and diagnosis 2023 ·British Journal of Haematology ·Barbara J. Bain, Yvonne Daniel, Joan Henthorn, Barbara De la Salle, (unknown), Noémi Roy, (unknown), (unknown), David C. Rees	15
3	Update on the diagnosis and management of the autosomal dominant acute hepatic porphyrias 2022 ·Journal of Clinical Pathology ·(unknown), (unknown), Penelope E. Stein, David C. Rees, Mike Badminton	4
4	Initial Safety and Efficacy Results from the Phase II, Multicenter, Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell Disease (SCD) 2021 ·Blood ·Matthew M. Heeney, David C. Rees, Mariane de Montalembert, Isaac Odame, R. Clark Brown, Yasser Wali, Thu Thuy Nguyen, Du Lam, (unknown), Julie Kanter	7
5	Genetic Analysis of Patients With Sickle Cell Anemia and Stroke Before 4 Years of Age Suggest an Important Role for Apoliprotein E 2020 ·Circulation Genomic and Precision Medicine ·John Brewin, Alexander Smith, (unknown), Sanjay Tewari, (unknown), Sarah Wilkinson, Valentine Brousse, Baba Inusa, Stephan Menzel, David C. Rees	8
6	Beneficial effects of adenotonsillectomy in children with sickle cell disease 2020 ·ERJ Open Research ·Ilaria Liguoro, Michele Arigliani, (unknown), (unknown), Subarna Chakravorty, Cara Bossley, (unknown), David C. Rees, Baba Inusa, Atul Gupta	4
7	Prevention of Morbidity in Sickle Cell Disease Phase II (Improvement of Pain and Quality of Life in Children with Sickle Cell Disease with Auto-adjusting Continuous Positive Airways Pressure: Phase II) (POMS 2b pediatric cohort) 2017 ·Blood ·April Slee, Jamie M. Kawadler, (unknown), (unknown), David C. Rees, (unknown), Jo Howard, Swee Lay Thein, Simon S. Skene, (unknown), (unknown), (unknown), Dawn E. Saunders, Johanna Gavlak, (unknown), (unknown), Christina Liossi, Fenella J. Kirkham, Baba Inusa	4
8	Autoimmune Liver Disease in Children with Sickle Cell Disease 2017 ·The Journal of Pediatrics ·(unknown), Emer Fitzpatrick, Maesha Deheragoda, Annamaria Deganello, Giorgina Mieli‐Vergani, Susan E. Height, David C. Rees, Nedim Hadžić, Marianne Samyn	18
9	Update review of the acute porphyrias 2016 ·British Journal of Haematology ·Penelope E. Stein, Michael N. Badminton, David C. Rees	104
10	Sickle cell disease and 5-HMF: the search for effective treatments 2015 ·Drugs of the Future ·John S. Gibson, (unknown), (unknown), David C. Rees	3
11	The role of ligand efficiency metrics in drug discovery breakdown → 2014 ·Nature Reviews Drug Discovery ·Andrew L. Hopkins, György M. Keserű, Paul D. Leeson, David C. Rees, Charles H. Reynolds	819
12	Morbidity pattern of sickle cell disease in India: A single centre perspective 2013 ·SHILAP Revista de lepidopterología ·Sanjay Tewari, David C. Rees	9
13	The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation. 2012 ·Health Technology Assessment ·Mary Gemma Cherry, J Greenhalgh, Leeza Osipenko, (unknown), Angela Boland, Y Dündar, Kevin Marsh, Rumona Dickson, David C. Rees	34
14	Outcome of adults with sickle cell disease admitted to critical care – experience of a single institution in the UK 2010 ·British Journal of Haematology ·Kate Gardner, (unknown), Jack Bartram, Marlene Allman, Moji Awogbade, David C. Rees, (unknown), Swee Lay Thein	23
15	The presence of α‐thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease 2008 ·British Journal of Haematology ·Nisha Vasavda, (unknown), David C. Rees, Sue Height, Jo Howard, Swee Lay Thein	16
16	Hydroxyurea therapy lowers circulating DNA levels in sickle cell anemia 2008 ·American Journal of Hematology ·Pinar Ulug, Nisha Vasavda, Rohan Kumar, (unknown), Moji Awogbade, (unknown), David C. Rees, Stephan Menzel, Swee Lay Thein	7
17	Factor V Leiden Mutation Screened by PCR and Detected with Lanthanide-Labeled Probes 2001 ·Genetic Testing ·(unknown), (unknown), David C. Rees	6
18	Hemoglobin F and Hemoglobin E/β-Thalassemia 2000 ·The American journal of pediatric hematology/oncology ·David C. Rees	15
19	Born to clot: the European burden 1999 ·British Journal of Haematology ·David C. Rees, Nicola H. Chapman, Matthew T. Webster, João Farias Guerreiro, Jacques Rochette, John Clegg	52
20	Genetic influences on bone disease in thalassemia. 1998 ·Blood ·Raveen Basran, David C. Rees, (unknown), Samuel C. Yiu, (unknown), D. J. Weatherall, N F Olivieri	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact